Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
But sasanlimab's use looks set to remain narrow.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
